Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03458897 · ClinicalTrials.gov registry record · NA

Quantitative MRI for Patients With Sickle Cell Disease Undergoing Hematopoietic Cell Transplant

A NA study of Sickle Cell Disease, sponsored by University of Michigan.

Completed
Registry status
NA
Development phase
7
Enrollment target
1
Study location

NCT03458897 is a NA study of Sickle Cell Disease that has completed, run by University of Michigan. The registered enrollment target is 7 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03458897, a NA study of Sickle Cell Disease, has completed, sponsored by University of Michigan.

COMPLETED
Registry status
NA
Development phase
7 participants
Enrollment target
1
Study location

Study Summary

The primary purpose of this research is to determine if it is feasible to perform serial magnetic resonance imaging (MRI) to evaluate the amount of bone marrow cells (also called cellularity) and iron stores before and after bone marrow transplantation for severe sickle cell disease.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST serial functional magnetic resonance imaging (MRI)

Study Locations (1)

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2018-05-03
Est. Completion 2020-09-01
Phase NA

Sponsor

University of Michigan

1,327 total trials

What the Registry Record Tells You About NCT03458897

The ClinicalTrials.gov registry entry for NCT03458897 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (98% lower). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which serial functional magnetic resonance imaging (MRI) is the first listed.

NCT03458897 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT03458897 about?

NCT03458897 is a clinical study titled "Quantitative MRI for Patients With Sickle Cell Disease Undergoing Hematopoietic Cell Transplant". The primary purpose of this research is to determine if it is feasible to perform serial magnetic resonance imaging (MRI) to evaluate the amount of bone marrow cells (also called cellularity) and iron stores before and after bone marrow transplantation for severe sickle cell disease.

What is the current status of trial NCT03458897?

This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2018-05-03. Estimated completion is 2020-09-01.

What conditions does trial NCT03458897 study?

This clinical trial studies the following conditions: Sickle Cell Disease.

What interventions are being tested in trial NCT03458897?

The interventions under investigation include: serial functional magnetic resonance imaging (MRI) (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03458897?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03458897 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.